Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.

Jena B, Dotti G, Cooper LJ.

Blood. 2010 Aug 19;116(7):1035-44. doi: 10.1182/blood-2010-01-043737. Epub 2010 May 3. Review.

PMID:
20439624
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Cartellieri M, Bachmann M, Feldmann A, Bippes C, Stamova S, Wehner R, Temme A, Schmitz M.

J Biomed Biotechnol. 2010;2010:956304. doi: 10.1155/2010/956304. Epub 2010 May 5. Review.

PMID:
20467460
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.

Curran KJ, Pegram HJ, Brentjens RJ.

J Gene Med. 2012 Jun;14(6):405-15. doi: 10.1002/jgm.2604. Review.

PMID:
22262649
[PubMed - indexed for MEDLINE]
4.

Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells.

Davies DM, Maher J.

Arch Immunol Ther Exp (Warsz). 2010 Jun;58(3):165-78. doi: 10.1007/s00005-010-0074-1. Epub 2010 Apr 6. Review.

PMID:
20373147
[PubMed - indexed for MEDLINE]
5.

Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.

Weibo P, Zhaoming Y.

Med Hypotheses. 2012 May;78(5):616-8. doi: 10.1016/j.mehy.2012.01.038. Epub 2012 Feb 12.

PMID:
22330890
[PubMed - indexed for MEDLINE]
6.

CARs in chronic lymphocytic leukemia -- ready to drive.

Hosing C, Kebriaei P, Wierda W, Jena B, Cooper LJ, Shpall E.

Curr Hematol Malig Rep. 2013 Mar;8(1):60-70. doi: 10.1007/s11899-012-0145-y. Review.

PMID:
23225251
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors.

Liu L, Sun M, Wang Z.

Cancer Lett. 2012 Mar;316(1):1-5. doi: 10.1016/j.canlet.2011.10.027. Epub 2011 Oct 29. Review.

PMID:
22099879
[PubMed - indexed for MEDLINE]
8.

Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions.

Chicaybam L, Sodré AL, Bonamino M.

Int Rev Immunol. 2011 Oct-Dec;30(5-6):294-311. doi: 10.3109/08830185.2011.595855. Review.

PMID:
22053970
[PubMed - indexed for MEDLINE]
9.

Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer.

Zhang Q, Li H, Yang J, Li L, Zhang B, Li J, Zheng J.

Curr Gene Ther. 2013 Feb;13(1):65-70. Review.

PMID:
23256743
[PubMed - indexed for MEDLINE]
10.

Chimeric antigen receptor modified T cell therapy for B cell malignancies.

Turtle CJ.

Int J Hematol. 2014 Feb;99(2):132-40. doi: 10.1007/s12185-013-1490-x. Epub 2013 Dec 14. Review.

PMID:
24338745
[PubMed - indexed for MEDLINE]
11.

Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity.

Kebriaei P, Kelly SS, Manuri P, Jena B, Jackson R, Shpall E, Champlin R, Cooper LJ.

Front Biosci (Schol Ed). 2012 Jan 1;4:520-31. Review.

PMID:
22202074
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors.

Fujiwara H.

Int J Hematol. 2014 Feb;99(2):123-31. doi: 10.1007/s12185-013-1493-7. Epub 2013 Dec 19. Review.

PMID:
24352938
[PubMed - indexed for MEDLINE]
13.

CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.

Gilham DE, Debets R, Pule M, Hawkins RE, Abken H.

Trends Mol Med. 2012 Jul;18(7):377-84. doi: 10.1016/j.molmed.2012.04.009. Epub 2012 May 19. Review.

PMID:
22613370
[PubMed - indexed for MEDLINE]
14.

Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.

Shirasu N, Kuroki M.

Anticancer Res. 2012 Jun;32(6):2377-83. Review.

PMID:
22641678
[PubMed - indexed for MEDLINE]
15.

Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy.

Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK.

Blood. 2002 Mar 15;99(6):2009-16.

PMID:
11877273
[PubMed - indexed for MEDLINE]
Free Article
16.

Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.

Ma Q, Gomes EM, Lo AS, Junghans RP.

Prostate. 2014 Feb;74(3):286-96. doi: 10.1002/pros.22749.

PMID:
24174378
[PubMed - indexed for MEDLINE]
17.

Grafting T cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant diseases.

Hombach A, Pohl C, Reinhold U, Abken H.

Hybridoma. 1999 Feb;18(1):57-61. Review.

PMID:
10211789
[PubMed - indexed for MEDLINE]
18.

Treating cancer with genetically engineered T cells.

Park TS, Rosenberg SA, Morgan RA.

Trends Biotechnol. 2011 Nov;29(11):550-7. doi: 10.1016/j.tibtech.2011.04.009. Epub 2011 Jun 12. Review.

PMID:
21663987
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.

Hillerdal V, Ramachandran M, Leja J, Essand M.

BMC Cancer. 2014 Jan 18;14:30. doi: 10.1186/1471-2407-14-30.

PMID:
24438073
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19.

Singh H, Huls H, Kebriaei P, Cooper LJ.

Immunol Rev. 2014 Jan;257(1):181-90. doi: 10.1111/imr.12137. Review.

PMID:
24329797
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk